Advertise on podcast: 340Banter Podcast

In this episode of 340Banter, Lisa Nelson, Chief Pharmacy Officer at Unity Care Northwest, joins the team to examine how broader changes in the drug pricing market are creating downstream impacts for the 340B Program. The conversation explores the removal of the Medicaid AMP cap, changes in list prices and penny pricing, and the implementation of Maximum Fair Prices under the Inflation Reduction Act. The team discusses how these shifts can affect 340B savings and pharmacy reimbursement, creating new challenges for health centers trying to forecast revenue and plan their budgets. They also look ahead to Medicare inflationary rebates and the Part D 340B claims data repository, while discussing the uncertainty health centers face as policies and manufacturer practices continue to evolve.

Recorded live at the RWC 340B Grantee Conference in Houston, this episode of 340Banter features Michael Thompson, Managing Director for RWC 340B, for a conversation about how the conference has grown and evolved alongside the grantee community. Michael discusses how attendee feedback helps shape conference programming, how RWC 340B has expanded its reach to more grantee types, and the work behind bringing continuing education opportunities to attendees. The conversation also looks ahead at future conference priorities and how sharing ideas across the grantee community can help organizations adapt successful approaches to their own programs.

Recorded live at the RWC 340B Grantees Conference in Houston, this episode of 340Banter examines the growing operational impact of manufacturer policies requiring claims data from entity-owned pharmacies. The conversation covers the challenges pharmacies face in extracting and formatting data, the importance of aligning the correct 340B ID with wholesaler purchasing accounts, and how pharmacies can navigate the 45-day claims submission window while minimizing unnecessary reversals. The team also clarifies current entity-owned pharmacy requirements within the Truzo platform and discusses how covered entities can respond when manufacturer policies conflict with state data submission laws. Practical guidance is also shared on distributing the workload across pharmacy teams as these requirements continue to evolve.

Manufacturer Good Faith Inquiries (GFIs) are becoming increasingly important for 340B covered entities. But what triggers a GFI, and how should an FQHC respond? In this episode, the FQHC 340B Compliance team discusses the rise in Manufacturer Good Faith Inquiries and how increased access to 340B transaction data is allowing manufacturers to identify potential compliance concerns. The conversation covers common GFI triggers, including potential Medicaid duplicate discounts and unusual purchasing patterns, as well as what can happen if an inquiry is not adequately addressed. You’ll also learn practical steps for responding to a GFI, including working with your TPA, consultants, legal counsel, and other 340B partners; reviewing the underlying claims and purchasing data; providing clear documentation; and addressing potential repayment obligations when necessary.

In this episode of 340Banter, we sit down with Lisa Nelson, Chief Pharmacy Officer at Unity Care Northwest, to discuss the advocacy behind Washington’s Contract Pharmacy Protection Bill. Lisa shares how health centers, pharmacy associations, public hospital partners, and other advocates built a coalition to move the legislation forward during Washington’s 60-day legislative session. We also discuss the Medicaid and federal funding arguments that helped gain support, transparency requirements for covered entities and manufacturers, and the pushback advocates faced throughout the process. For other states considering similar 340B protections, Lisa shares practical lessons from Washington’s experience with coalition building and legislative advocacy. Let’s connect: https://www.fqhc340b.com/ [email protected] (760) 780-7469

In this episode of 340Banter, we sit down with Christina Harbison, Senior Clinical Pharmacist at Prism Health North Texas, to discuss how the organization grew its long-acting injectable (LAI) program from 18 patients to approximately 700. Christina shares how Prism Health North Texas has navigated medication acquisition, prescription and medical benefits, buy-and-bill, prior authorizations, and payer requirements while expanding access to long-acting injectable options for HIV treatment and prevention. We also discuss the operational aspects of building an LAI program, including securing organizational buy-in, developing the right staffing model, verifying coverage prior to administration, and involving pharmacists in medication management and patient counseling. For health centers considering long-acting injectables or working to expand an existing program, Christina offers practical advice based on Prism Health North Texas' experience: start slowly, understand the financial risks, establish reliable processes, and ensure patients can maintain access to treatment over time. Let’s connect: https://www.fqhc340b.com/ [email protected] (760) 780-7469

In this episode of 340Banter, we sit down with Angela Sorber, Director of Pharmacy Service Line at Nevada Health Centers, to discuss the realities of managing 340B pharmacy operations across multiple in-house pharmacy locations. Angela shares how her team adapts to the unique needs of different patient populations while maintaining consistent operations across the organization. We discuss the importance of empowering local pharmacy leaders, using data to guide decision-making, and fostering strong communication across pharmacy teams. She also offers practical insights into balancing operational efficiency with patient access to medications. Whether you're managing one pharmacy or multiple locations, this conversation offers valuable takeaways on building scalable processes, supporting pharmacy teams, and delivering high-quality patient care. Let's connect: https://www.fqhc340b.com/ [email protected] (760) 780-7469

In this episode of 340Banter, we break down one of the biggest operational challenges facing health centers today: documenting clinic-administered drugs. For many organizations, paper logs and spreadsheets are no longer enough to keep up with evolving manufacturer requirements. As the industry moves toward rebate models and medical claims data submissions, gaps in documentation and billing could put 340B savings at risk. We discuss what these changes mean, the technology and workflow improvements health centers should be considering now, and why high-value medications like long-acting injectables and HIV treatments deserve special attention. If your organization is still relying on manual processes, this conversation will help you understand what's changing and how to prepare before these requirements become unavoidable.  Let’s connect: https://www.fqhc340b.com/ [email protected] (760) 780-7469

How often do HRSA Operational Site Visits (OSVs) occur, and what exactly are reviewers looking for during these important compliance assessments? In this episode of 340Banter, Chelsea Violette and Logan Yoho discuss recent updates to HRSA's Operational Site Visit (OSV) Protocol and how the changes help clarify expectations for health centers navigating compliance requirements. A key focus of the conversation is the Sliding Fee Discount Program (SFDP), an area that has historically created confusion during site visits. Chelsea and Logan break down the latest protocol updates, explain what has changed, and discuss how health centers can better prepare for OSV reviews by understanding HRSA's current expectations. Whether you're a CEO, COO, compliance officer, operations leader, or health center administrator, this episode provides practical insights to help your organization stay informed and prepared for HRSA oversight activities. Let’s connect: https://www.fqhc340b.com/ [email protected] (760) 780-7469

What do all those 340B financial reports actually mean, and how can organizations make sense of them when every vendor seems to report data differently? In this episode of 340Banter, Chelsea Violette and Logan Yoho sit down with Michael Gonzalez, Founder of FQHC 340B Compliance, to unpack one of the biggest operational challenges facing 340B Programs today: navigating non-standardized financial reporting across TPAs, pharmacy platforms, and vendor systems. From confusing terminology and inconsistent report formats to understanding what metrics truly matter, this conversation explores how covered entities can better track the financial performance and overall health of their 340B Program. Michael shares practical strategies for improving visibility into savings, identifying reporting gaps, monitoring trends over time, and creating a more proactive approach to financial oversight and compliance. Whether you're a 340B coordinator, CFO, pharmacy leader, or compliance professional, this episode delivers valuable insight into how organizations can strengthen financial monitoring, ask better questions of their vendors, and maintain a clearer pulse on the sustainability and performance of their 340B operations. Let’s connect: https://www.fqhc340b.com/ | [email protected]

What exactly is an Annual Single Audit, and why does it matter for organizations participating in the 340B Drug Pricing Program? In this episode of 340Banter, Chelsea Violette and Logan Yoho sit down with Michael Gonzalez, Founder of FQHC 340B Compliance, to break down the essentials of the Single Audit process and its critical connection to pharmacy operations within 340B Programs. Whether you're a compliance officer, healthcare administrator, or pharmacy leader, this episode delivers practical insights into how federal audit requirements impact covered entities, funding accountability, and 340B Program integrity. Learn how Single Audits evaluate financial controls, ensure compliance with federal regulations, and influence pharmacy partnerships and contract pharmacy oversight.

Donavan received his Bachelor’s degree in pharmacy from the University of Utah College of Pharmacy in 1995. His past work experience includes being a retail pharmacist at Albertsons, a Director of Pharmacy at Gunnison Valley Hospital, and a Director of Pharmacy at Central Valley Medical Center. While at Gunnison Valley Hospital, he sat on the Pharmacy and Therapeutics committee and was an active member of the Gunnison Valley Hospice program. In addition, Donavan was an adjunct faculty member at the Snow College Richfield Allied Health department for 6 years, where he developed and taught the pharmacy technician program. In 2005, he started his current position as the Director of Pharmacy at the Wayne Community Health Center in Bicknell, Utah. In 2007, Donavan received the Stephen D. Ratcliff award from the Association of Utah Community Health Centers in recognition of his efforts as a positive visionary leader. From spring 2012 to 2014, Donavan served 2 years as a 340B Peer-to-Peer Mentor with the American Pharmacists Association Federal Contracts and Grants. During this time, he received the Peer All-Star Award and Peer Spirit Award. Donavan sits on the Apexus 340B Prime Vendor Program Advisory Council for Federally Qualified Health Centers. As a Director of Pharmacy, Donavan has helped spearhead the chronic pain management program at Wayne Community Health Center. This program received recognition in 2010 from the Sevier Valley Substance Abuse Coalition for its outstanding efforts in the fight against prescription drug abuse. He sits on the P&T committee and is an active member of the clinical multidisciplinary team and the Emergency room team. During his employment with Wayne Community Health Center, he has helped implement and manage the acute coronary treatment program, including the usage of thrombolytics in a rural clinic 60 miles away from the nearest hospital and 160 miles from the nearest acute cardiac center. In 2018 and 2019, Donavan and Zackery Taylor, PharmD. Wayne Community Health Center became the first open-door telepharmacy-retail pharmacy for a remote dispensing site located in Green River, Utah.

On this episode of 340Banter, Donovan Smith, CEO of Wayne Community Health Centers, details the real-world impact of the IRA’s Maximum Fair Price (MFP) implementation. He explains how claims are being misattributed to 340B, the challenges of a dual inventory model in a remote pharmacy, the financial strain from denied rebates and low dispensing fees, and the risks to patient access. Donovan also discusses advocacy efforts and potential fixes to make the process fairer for small, rural safety-net providers.

In this episode, we explore a powerful and timely topic: How to reteach yourself how to learn. Whether you’re returning to school, starting a new career, rebuilding confidence, or simply feeling stuck, learning as an adult can feel very different than it did before. The good news? Learning is a skill, and it can be rebuilt. This conversation dives into the mindset shifts, habits, and strategies that help you become a better learner again, especially in a world full of distractions, burnout, and information overload. If you’ve ever thought, “I don’t know how to learn anymore,” this episode is for you. 👉 Subscribe for more conversations on personal growth, mindset, productivity, and lifelong learning.

In this episode of the 340Banter Podcast, co-hosts Chelsea Violette and Logan Yoho take a closer look at MFP Drugs, the first prescription medications selected for Maximum Fair Price (MFP) under Medicare’s new drug pricing authority. With Medicare now negotiating prices for some of the most widely used and expensive drugs in the U.S., the spotlight is on how these MFP drug selections will affect patients, manufacturers, providers, and the broader healthcare marketplace. Chelsea and Logan break down what it means to be an “MFP drug,” how the negotiation process works, and what stakeholders should be watching as implementation continues. If you work in healthcare policy, pharmacy, drug pricing, Medicare, or 340B compliance, this is a must-listen conversation on one of the biggest shifts in pharmaceutical reimbursement in decades. 👉 Subscribe for more weekly discussions on 340B, Medicare reform, drug pricing policy, and healthcare legislation.